Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
243
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma

Qingyuan Zhanga Department of Internal Medicine-Oncology, Cancer Hospital of Harbin Medical University, Harbin, ChinaView further author information
,
Rong Taob Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, ChinaView further author information
,
Zhenyu Lic The Affiliated Hospital of Xuzhou Medical University, Xuzhou, ChinaView further author information
,
Haiyi Guod BeiGene (Shanghai) Co., Ltd, Shanghai, ChinaView further author information
,
Meng Jie BeiGene (Beijing) Co., Ltd, Beijing, ChinaView further author information
,
Lu Zhangd BeiGene (Shanghai) Co., Ltd, Shanghai, ChinaView further author information
,
Jane Huangf BeiGene USA, Inc, San Mateo, CA, USAView further author information
,
Fu Linae BeiGene (Beijing) Co., Ltd, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0003-2264-079XView further author information
ORCID Icon,
Jinhua Zhongd BeiGene (Shanghai) Co., Ltd, Shanghai, ChinaView further author information
&
Jianfeng Zhoug Tongji Hospital, Tongji Medical College, Wuhan, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 2503-2506 | Received 03 Jan 2022, Accepted 04 May 2022, Published online: 19 Jul 2022

References

  • Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
  • Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99(4):1136–1143.
  • Rosenwald A, Wright G, Chan WC, Lymphoma/Leukemia Molecular Profiling Project, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
  • Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
  • Fowler N, Nastoupil L, de Vos S, et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study. Blood. 2015;126(23):470–470.
  • Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56.
  • Woyach JA, Blachly JS, Byrd JC, et al. Acalabrutinib plus obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discov. 2020;10(3):394–405.
  • Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–1099.
  • Li N, Sun Z, Liu Y, et al. BGB-3111 is a novel and highly selective bruton’s tyrosine kinase (BTK) inhibitor. Cancer Res. 2015;75(15 suppl)Abstract:2597.
  • Tam CS, Grigg AP, Opat S, et al. The BTK inhibitor, BGB-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):832–832.
  • Tam CS, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020;4(19):4802–4811.
  • Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG Ly.12. J Clin Oncol. 2014;32(31):3490–3496.
  • Wilson WH, Phillips T, Popplewell L, et al. Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;62(9):2094–2106.
  • Younes A, Sehn LH, Johnson P, PHOENIX investigators, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma . J Clin Oncol. 2019;37(15):1285–1295.
  • Kedmi M, Ribakovsy E, Benjamini O, et al. Ibrutinib, bendamustine, rituximab combination for relapsed and refractory aggressive B cell lymphoma—interim analysis of phase II clinical trial. Blood. 2018;132(Supplement 1)Abstract:4186–4186.
  • Goy A, Ramchandren R, Ghosh N, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024–1036.
  • Bartlett NL, Costello BA, Laplant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial[J]. Blood. 2018;131(2):182–190.
  • Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA trial: zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res. 2021;27(23):6323–6332.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.